Ni Guo

The ATC score: a novel efficacy scoring model for risk stratification and personalized management of unresectable HCC patients receiving TACE-lenvatinib-PD-1 inhibitor therapy

Unresectable Hepatocellular Carcinoma (uHCC) has limited therapeutic options. The combination therapy of Transarterial chemoembolization (TACE), lenvatinib, and PD-1 inhibitors (T-L-P) shows promising efficacy, but a tool to predict individual treatment responses is lacking. To d...